US Stock MarketDetailed Quotes

NEXI NexImmune

Watchlist
  • 3.1600
  • -0.1400-4.24%
Close May 22 16:00 ET
  • 3.4900
  • +0.3300+10.44%
Post 16:40 ET
4.33MMarket Cap-131P/E (TTM)

About NexImmune Company

NexImmune, Inc. is a clinical stage biotechnology company, which engages in the development of novel approach to immunotherapy designed to employ the body's own T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. Its product candidates are NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM. The company was founded by Kenneth C. Carter, Jonathan Schneck, and Mathias Oelke on June 7, 2011 and is headquartered in Gaithersburg, MD.

Company Profile

SymbolNEXI
Company NameNexImmune
Listing DateFeb 12, 2021
Issue Price17.00
Founded2011
CEOMs. Kristi Jones
MarketNASDAQ
Employees6
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address9119 Gaither Road
CityGaithersburg
ProvinceMaryland
CountryUnited States of America
Zip Code20877
Phone1-301-825-9810

Company Executives

  • Name
  • Position
  • Salary
  • Kristi Jones
  • Director, President and Chief Executive Officer
  • 2.15M
  • Mathias Oelke
  • Chief Scientific Officer
  • 736.27K
  • Albert N. Marchio
  • Principal Financial Officer and Principal Accounting Officer
  • --
  • Dr. Sol J. Barer,PhD
  • Chairman of the Board
  • 102.00K
  • Grant Verstandig
  • Independent Director
  • 44.00K
  • Alan S. Roemer
  • Independent Director
  • 62.50K
  • Dr. Zhengbin Yao, PhD
  • Independent Director
  • 64.00K
  • Leena Gandhi
  • Independent Director
  • 26.15K
  • Paul D’Angio, R.Ph.
  • Independent Director
  • 62.50K
  • Dr. Timothy Bertram, PhD
  • Independent Director
  • 57.50K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg